STJ  St. Jude Medical Inc.

Exchange

NYSE

Sector

Health Care

Industry

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Market Cap.

17.826B

Vuru Grade

63.93/100

Current Price

$62.62
-0.845 (-1.33%)

Growth Price

$39.55
Overvalued by 36.83%

Stability Price

$20.48
Overvalued by 67.29%

Company Metrics

  • 20.44 P/E
  • 3.24 P/S
  • 4.54 P/B
  • 3.104 EPS
  • 13.07% Cash ROIC
  • 0.99 Cash Ratio
  • 1.04 / 1.64% Dividend
  • 1.54M Avg. Vol.
  • 284.69M Shares
  • 17.826B Market Cap.

Company Description

St. Jude Medical, Inc. develops, manufactures, and distributes cardiovascular and implantable neurostimulation medical devices worldwide. It operates in four segments: Cardiac Rhythm Management, Cardiovascular, Atrial Fibrillation, and Neuromodulation. The Cardiac Rhythm Management segment offers products for cardiac arrhythmias, or irregular heart beats. Its products include tachycardia implantab...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

St. Jude Medical Gets Clearance for PCI Optimization System
Zacks.com - Sep 17, 2014
The OPTIS Integrated system also integrates St. Jude Medical PressureWire FFR measurement technology to provide access to critical hemodynamic information during PCI.
St. Jude Medical Comes Up with Positive CardioMEMS Data
Zacks.com - Sep 17, 2014
St. Jude Medical Inc. (STJ - Analyst Report) recently revealed a new data analysis from its CHAMPION trial which was conducted to evaluate the safety and efficacy of the company's CardioMEMS Heart Failure (HF) System for patients with New York Heart ...
St. Jude Medical Comes Up with Positive CardioMEMS Data - Analyst Blog
NASDAQ - Sep 17, 2014
St. Jude Medical Inc. ( STJ ) recently revealed a new data analysis from its CHAMPION trial which was conducted to evaluate the safety and efficacy of the company's CardioMEMS Heart Failure (HF) System for patients with New York Heart Association ...
St. Jude Medical Reports Positive 12-Month EnligHTN Data
Zacks.com - Sep 15, 2014
St. Jude Medical Inc. recently announced 12-month data outcome from its EnligHTN III study. The data confirms the continuation of safe, rapid and effective treatment with the company's second-generation EnligHTN renal denervation system for patients ...
St. Jude Medical (STJ) Repors Presentation of Encouraging EnligHTN III Data - StreetInsider.com (subscription)
St. Jude Medical Enters Oversold Territory
Forbes - Sep 15, 2014
In the case of St. Jude Medical, Inc., the RSI reading has hit 27.8 - by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 46.0.
St. Jude Medical Gets Clearance for PCI Optimization System - Analyst Blog
NASDAQ - Sep 17, 2014
Currently, St. Jude Medical carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the medical products industry include ICU Medical, Inc. ( ICUI ), Abaxis, Inc. ( ABAX ), and Symmetry Medical, Inc. ( SMA ). ICU Medical sports a Zacks Rank #1 ...
St. Jude Medical Settles FDA Warnings Letter for Texas Plant
Zacks.com - Aug 27, 2014
St. Jude Medical Inc. (STJ - Analyst Report) revealed that U.S. Food and Drug Administration (FDA) notified that the company has addressed issues cited in the warning letter for its Plano facility in Texas.
St. Jude Medical Resolves FDA Warning Letter for Plano Facility - MarketWatch
St. Jude Medical Gets Award for Leadless Pacemaker Again
Zacks.com - Sep 16, 2014
St. Jude Medical Inc. (STJ - Analyst Report) revealed that it has received the Most Promising New Product Award at the 2014 Phoenix Conference - the 21st annual conference for executive leaders in the medical device industry - for its Nanostim leadless ...
Boston Properties Takes Over #241 Spot From St. Jude Medical
Forbes - Sep 3, 2014
Market capitalization is an important data point for investors to keep an eye on, for various reasons. The most basic reason is that it gives a true comparison of the value attributed by the stock market to a given company's stock. Many beginning ...
Positive Data on St. Jude Medical Quadripolar Lead System - Analyst Blog - NASDAQ
St. Jude Medical Announces Launch of OPTIS Integrated System
MarketWatch - Sep 15, 2014
ST. PAUL, Minn., Sep 15, 2014 (BUSINESS WIRE) -- St. Jude Medical, Inc. STJ, -1.61% a global medical device company, today announced the company has secured CE Mark and FDA clearance for the new OPTISTM Integrated System.
Company Update (NYSE:STJ): St. Jude Medical Announces Launch of OPTISTM ... - Jutia Group
St. Jude Medical OCT imaging system receives FDA and CE Mark approvals - BioOptics World